Accès gratuit
Numéro
Therapie
Volume 67, Numéro 4, Juillet-Août 2012
Page(s) 319 - 327
Section Recherche et développement / Research and Development
DOI https://doi.org/10.2515/therapie/2012043
Publié en ligne 1 novembre 2012
  1. Paintaud G, Tonelli D, Postaire E, et al. Biothérapies : des médicaments comme les autres ? Therapie 2007; 62: 229-34 [CrossRef] [EDP Sciences] [PubMed]
  2. Paintaud G, Lejarre F, Ternant D, et al. Les anticorps monoclonaux : une avancée thérapeutique récente et majeure. Therapie 2009; 64: 1-7 [CrossRef] [EDP Sciences] [PubMed]
  3. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8 [CrossRef] [PubMed]
  4. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-57 [CrossRef] [PubMed]
  5. Congy-Jolivet N, Probst A, Watier H, et al. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol 2007; 64: 226-33 [CrossRef] [PubMed]
  6. Lejeune J, Thibault G, Cartron G, et al. Rôle des récepteurs à la portion Fc des IgG (FcγRs) dans l’activité des anticorps thérapeutiques. Bull Cancer 2010; 97: 511-22 [PubMed]
  7. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-8 [CrossRef] [PubMed]
  8. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-96 [CrossRef] [PubMed]
  9. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-9 [CrossRef] [PubMed]
  10. Béliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FcgRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141: 109-19 [CrossRef] [PubMed]
  11. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgRIIIA/CD16. Br J Haematol 2008; 140: 635-43 [CrossRef] [PubMed]
  12. EMA. Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. 2008 CHMP/BWP/157653/2007. http://www.ema.europa.eu
  13. EMA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2007 EMEA/CHMP/BMWP/14327/2006. http://www.ema.europa.eu
  14. EMA. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2010 EMEA/CHMP/BMWP/86289/2010. http://www.ema.europa.eu
  15. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28 [CrossRef] [PubMed]
  16. Afssaps. Essais cliniques de première administration à l’Homme, en dose unique d’un médicament expérimental (nouvelle substance active) : choix de la première dose, de la progression de dose et protocole d'administration aux volontaires. 2006. http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Premiere-administration-d-un-medicament-experimental-chez-l-homme-l-Afssaps-diffuse-des-recommandations-sur-les-essais-cliniques-de-phase-I/(language)/fre-FR
  17. EMA. Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products. 2007 CHMP/SWP/28367/2007. http://www.ema.europa.eu
  18. EMA. Guideline on similar biological medicinal products containing monoclonal antibodies. 2010 EMEA/CHMP/BMWP/403543/2010. http://www.ema.europa.eu
  19. Loisel S, Ohresser M, Pallardy M, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62: 34-42 [CrossRef] [PubMed]
  20. Paintaud G. Pharmacocinétique des anticorps monoclonaux. Med Sci (Paris) 2009; 25: 1057-62 [CrossRef] [EDP Sciences] [PubMed]
  21. Magdelaine-Beuzelin C, Ohresser M, Watier H. FcRn, un récepteur d’IgG aux multiples facettes. Med Sci (Paris) 2009; 25: 1053-6 [CrossRef] [EDP Sciences] [PubMed]
  22. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005; 5: S37-S47 [CrossRef] [PubMed]
  23. Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2009; 37: 25-47 [CrossRef] [PubMed]
  24. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9 [CrossRef] [PubMed]
  25. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13: R105 [CrossRef] [PubMed]
  26. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358: 1109-17 [CrossRef] [PubMed]
  27. Zheng Y, Scheerens H, Davis JC Jr, et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 2011; 89: 283-90 [CrossRef] [PubMed]
  28. Grudé F, Roué V, Beauchamp C, et al. Real cost linked to the introduction of targeted therapies (bevacizumab, cetuximab) and conventional chemotherapies in the treatment of metastatic colorectal cancer. Gastrointestinal Cancers Symposium, San Francisco 2009, A330
  29. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-8 [CrossRef] [PubMed]
  30. Metges JP, Grudé F, Faroux R, et al. FOLFIRI bevacizumab in unresectable metastatic colorectal cancer in the true life, feasible in elderly patients: results of the cohort from OMIT Bretagne-Pays de Loire. Gastrointestinal Cancers Symposium, San Francisco, A398
  31. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2011; 50 : 222-9 [CrossRef] [PubMed]